CSPC Megalith Biopharmaceutical Co.,Ltd. clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 0 with minor changes only.

1. Notable

   SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic…SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma

   Primary completion pushed from Jun 30, 2026 to Jun 30, 2028

   Also in this update: Enrollment increased: 70 → 110 participants; Study completion pushed from Dec 31, 2027 to Dec 31, 2028

   CSPC Megalith Biopharmaceutical Co.,Ltd.·Phase 2· NCT07254585· Registry history of NCT07254585 on ClinicalTrials.gov (opens the registry)

   Oct 19, 2026

2. Notable

   SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary…SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

   Primary endpoint(s) modified

   Also in this update: Recruitment opened

   CSPC Megalith Biopharmaceutical Co.,Ltd.·Phase 3· NCT07708753· Registry history of NCT07708753 on ClinicalTrials.gov (opens the registry)

   Sep 23, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.